A CD56− immunoblastoid variant of blastic plasmacytoid dendritic cell neoplasm

Abstract

AbstractBlastic plasmacytoid dendritic cell neoplasm (BPDCN) is an aggressive malignant hematologic neoplasm arising from plasmacytoid dendritic cells. It is a very rare tumor that constitutes less than 0.1% of all hematologic malignancies. Most patients with BPDCN present clinically with cutaneous lesions as the first sign of disease. Immunophenotypic variability with aberrant marker profiles has been reported. We report a case of a transcription factor 4 (TCF‐4) + BPDCN, with negative CD56 expression in an 85‐year‐old woman with multiple skin nodules. A punch biopsy revealed a diffuse, monomorphous, and non‐epidermotropic cell infiltrate involving the entire dermis. The infiltrate was composed of intermediate‐sized cells with immunoblastoid morphology, which is an unusual morphologic variant. The neoplastic cells were strongly positive for CD45 and co‐expressed CD4, CD123, TCF‐4, BCL‐2, and CD10. The Ki‐67 proliferative rate was very high (90%). Negative immunostains included CD56, an unusual finding in BPDCN. This case illustrates the challenges encountered in the diagnosis of this entity, particularly in unusual morphologic variants and phenotypes. The elucidation of molecular signatures and development of targeted therapies for its management have been recently introduced and differ from acute myeloid leukemias. Hence, accurate diagnosis of BPDCN is critical for dermatopathologists.